JPMorgan Chase & Co. Purchases 46,216 Shares of OraSure Technologies, Inc. (NASDAQ:OSUR)

JPMorgan Chase & Co. grew its position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 5.8% in the 3rd quarter, HoldingsChannel reports. The firm owned 847,933 shares of the medical instruments supplier’s stock after acquiring an additional 46,216 shares during the quarter. JPMorgan Chase & Co.’s holdings in OraSure Technologies were worth $3,621,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of OSUR. BNP Paribas Financial Markets raised its holdings in shares of OraSure Technologies by 27.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 855,951 shares of the medical instruments supplier’s stock valued at $3,655,000 after buying an additional 183,191 shares in the last quarter. Franklin Resources Inc. grew its position in OraSure Technologies by 28.5% during the third quarter. Franklin Resources Inc. now owns 269,269 shares of the medical instruments supplier’s stock valued at $1,091,000 after acquiring an additional 59,723 shares during the last quarter. Deerfield Management Company L.P. Series C raised its stake in shares of OraSure Technologies by 428.6% during the second quarter. Deerfield Management Company L.P. Series C now owns 152,003 shares of the medical instruments supplier’s stock worth $648,000 after acquiring an additional 123,248 shares in the last quarter. Barclays PLC lifted its holdings in shares of OraSure Technologies by 182.6% in the 3rd quarter. Barclays PLC now owns 195,793 shares of the medical instruments supplier’s stock worth $836,000 after acquiring an additional 126,503 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of OraSure Technologies by 1.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,797,814 shares of the medical instruments supplier’s stock valued at $7,678,000 after purchasing an additional 32,929 shares in the last quarter. 93.50% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, StockNews.com upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating in a research report on Friday.

OraSure Technologies Price Performance

OSUR opened at $3.65 on Friday. The stock’s 50 day simple moving average is $3.81 and its 200 day simple moving average is $4.09. The firm has a market cap of $272.25 million, a price-to-earnings ratio of 24.33 and a beta of 0.05. OraSure Technologies, Inc. has a 1 year low of $3.52 and a 1 year high of $8.30.

OraSure Technologies (NASDAQ:OSUR) last issued its earnings results on Wednesday, November 6th. The medical instruments supplier reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.02. OraSure Technologies had a net margin of 5.07% and a return on equity of 3.55%. The firm had revenue of $39.92 million for the quarter, compared to analysts’ expectations of $38.97 million. During the same quarter last year, the business earned $0.27 earnings per share. The business’s revenue was down 55.2% on a year-over-year basis. As a group, sell-side analysts anticipate that OraSure Technologies, Inc. will post -0.08 EPS for the current year.

OraSure Technologies Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.